CD274 and diffuse large B-cell lymphoma: Atezolizumab, a humanized IgG1 anti-PD-L1 antibody, in combination with 6 cycles of R-CHOP followed by 12 months of consolidation, was evaluated in 42 untreated advanced DLBCL patients.